"We are encouraged by the Phase II results and activity of CR011-vcMMAE
in patients with metastatic melanoma that we announced concurrently today,
and we will be engaging in discussions with potential partners as we
develop plans for the advanced stages of development. The goal of a
partnership will be to support the financial, development and commercial
resources that will be required in advanced development, improving the risk
profile to CuraGen shareholders while maintaining upside potential," stated
Dr. Shannon. "We are also actively evaluating strategic opportunities that
can accelerate an increase in shareholder value."
Conference Call Details and Dial-in Information
Date: Monday, November 3, 2008
Time: 11:00 a.m. EDT
Dial-in: 877-272-5391 (domestic)
Webcast: Access available at http://www.curagen.com
A replay of the conference call will be available starting at 2:00 p.m. Eastern time on Monday, November 3, 2008 through Wednesday, December 3, 2008 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 71190212. An archive of the webcast will be available for 30 days at http://www.curagen.com.
|SOURCE CuraGen Corporation|
Copyright©2008 PR Newswire.
All rights reserved